Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Status:
RECRUITING
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.